Skip to main content

Table 2 Patient characteristics and treatment outcomes

From: Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients

Characteristics Patients, n (%) Median (range)
Sex
 Male 101 (49.0)  
 Female 105 (51.0)  
Age at diagnosis, year   43 (13–76)
 ≥ 43 106 (51.5)  
 < 43 100 (48.5)  
BM blasts, %   67.2 (22–97.8)
 ≥ 67.2 100 (48.5)  
 < 67.2 99 (48.1)  
 Unknown 7 (3.4)  
WBC, ×109/L   20.7 (0.29–412.5)
 ≥ 20.7 104 (50.5)  
 < 20.7 102 (49.5)  
Hemoglobin, g/L   81 (20–138)
 ≥ 81 103 (50.0)  
 < 81 101 (49.0)  
 Unknown 2 (1.0)  
Platelets, ×109/L 206 38.5 (5–542)
 < 38.5 103 (50)  
 ≥ 38.5 103 (50)  
FAB classification
 M0 2 (1.0)  
 M1 14 (6.8)  
 M2 104 (50.5)  
 M4 31 (15.0)  
 M5 46 (22.3)  
 M6 7 (3.4)  
 M7 2 (1.0)  
Risk stratificationsa
 Low risk 35 (17.0)  
 Intermediate risk 118 (57.3)  
 High risk 53 (25.7)  
FLT3-ITD mutation
 Positive/negative 25/181 (12.1/87.9)  
NPM1 mutation
 Positive/negative 32/174 (15.5/84.5)  
KIT mutation
 Positive/negative 9/197 (4.4/95.6)  
CEBPA mutation
 Positive/negative 7/199 (3.4/96.6)  
Karyotype
 Normal 133 (64.6)  
 inv (16) 8 (3.9)  
 t (8;21) 11 (5.3)  
 t (6;9) 3 (1.5)  
 t (9;22) 1 (0.5)  
 t (9;11) 2 (1.0)  
 inv (3) 1 (0.5)  
 + 8 2 (1.0)  
 − 7 1 (0.5)  
 Other 44 (21.4)  
Treatment response
 CR 176 (85.4)  
  CR after 1st course 125 (60.7)  
  CR after 2nd course 51 (24.8)  
 Non-CR 30 (14.6)  
Treatment outcome
 Death 31 (15.0)  
 Relapse 21 (10.2)  
Adverse events (grade ≥ 2)
 Myelosuppression 168 (81.6)  
 Liver function damage 23 (11.2)  
 Cardiotoxicity 11 (5.3)  
 Gastrointestinal reaction 66 (32.0)  
  1. BM bone marrow, WBC white blood cell, FAB French–American–British
  2. aClassified according to NCCN guidelines version 1.2015 acute myeloid leukemia